1040 related articles for article (PubMed ID: 19798117)
1. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion.
Wu WC; Cheng KC; Wu HJ
Eye (Lond); 2009 Dec; 23(12):2215-22. PubMed ID: 19218991
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion.
Patel PJ; Zaheer I; Karia N
Eye (Lond); 2008 Jan; 22(1):60-4. PubMed ID: 16902493
[TBL] [Abstract][Full Text] [Related]
6. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study.
Hou J; Tao Y; Jiang YR; Li XX; Gao L
Chin Med J (Engl); 2009 Nov; 122(22):2695-9. PubMed ID: 19951598
[TBL] [Abstract][Full Text] [Related]
9. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
Sohn HJ; Han DH; Lee DY; Nam DH
Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
11. [Macular oedema and intravitreal triamcinolone injections].
Gunnlaugsdóttir E; Oehman DO; Gunnarsdóttir SG; Stefánsson E
Laeknabladid; 2006 Dec; 92(12):847-57. PubMed ID: 17206015
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema.
Bakri SJ; Shah A; Falk NS; Beer PM
Eye (Lond); 2005 Jun; 19(6):686-8. PubMed ID: 15332099
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study.
Krepler K; Ergun E; Sacu S; Richter-Müksch S; Wagner J; Stur M; Wedrich A
Acta Ophthalmol Scand; 2005 Oct; 83(5):600-4. PubMed ID: 16188000
[TBL] [Abstract][Full Text] [Related]
14. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion.
Hayashi K; Hayashi H
Am J Ophthalmol; 2005 Jun; 139(6):972-82. PubMed ID: 15953425
[TBL] [Abstract][Full Text] [Related]
16. [Role of intravitreal bevacizumab for resistant macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide].
Le Moigne O; Duncombe A; Portmann A; Muraine M; Genevois O
J Fr Ophtalmol; 2012 Nov; 35(9):700-4. PubMed ID: 22925843
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of early injection of intravitreal triamcinolone acetonide (IVTA) versus delayed injection for macular edema resulting from retinal vein occlusion].
Saleh M; Gaucher D; Letsch J; Bourcier T; Speeg-Schatz C
J Fr Ophtalmol; 2011 Jun; 34(6):355-61. PubMed ID: 21652108
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections.
Alshareef RA; Garg SJ; Hsu J; Vander J; Park C; Spirn MJ
J Ocul Pharmacol Ther; 2014 Aug; 30(6):512-6. PubMed ID: 24828198
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
Ehlers JP; Decroos FC; Fekrat S
Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
